Research ArticleAccepted Article
Higher serum urate levels are associated with an increased risk for sudden cardiac death
Lisandro D. Colantonio, Richard J. Reynolds, Tony R. Merriman, Angelo Gaffo, Jasvinder A. Singh, Timothy B. Plante, Ninad S. Chaudhary, Nicole D. Armstrong, Elsayed Z. Soliman, Jeffrey R. Curtis, S. Louis Bridges Jr, Leslie Lang, George Howard, Monika M. Safford, Kenneth G. Saag, Paul Muntner and Marguerite Ryan Irvin
The Journal of Rheumatology June 2021, jrheum.210139; DOI: https://doi.org/10.3899/jrheum.210139
Lisandro D. Colantonio
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Richard J. Reynolds
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Tony R. Merriman
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Angelo Gaffo
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Jasvinder A. Singh
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Timothy B. Plante
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Ninad S. Chaudhary
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Nicole D. Armstrong
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Elsayed Z. Soliman
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Jeffrey R. Curtis
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
S. Louis Bridges Jr
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Leslie Lang
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
George Howard
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Monika M. Safford
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Kenneth G. Saag
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Paul Muntner
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Marguerite Ryan Irvin
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, United States; Department of Biochemistry, University of Otago, Dunedin, Aotearoa New Zealand; Birmingham Veterans Affairs Medical Center, Birmingham, AL, United States; Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, United States; Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC, United States; Department of Medicine, University of Colorado Denver, Denver, CO, United States; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, Weill Cornell Medical College, New York, NY, United States. Funding: This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Service. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIA. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. Additional funding was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute (NHLBI) and grant P50AR060772 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Representatives from the NHLBI or the NIMAS did not have any role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript. Conflict of interest: LDC receives research support from Amgen. AG receives research support from Amgen and honoraria from UpToDate. JAS receives consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Trio Health, Focus forward, Navigant consulting, Practice Point communications, Simply Speaking, the National Institutes of Health and the American College of Rheumatology, is member of the Executive Committee of Outcome Measures in Rheumatology (OMERACT), and is stockholder of Amarin pharmaceuticals and Viking therapeutics. MMS receives research support from Amgen. PM receives research support from Amgen and serves as a consultant for Amgen. KGS receives research support from Horizon, Takeda, Sobi, and Shanton, and serves as a consultant/advisor for Arthrosi, Atom Bioscience, LG Pharma, Mallinkrodt, Sobi, Horizon, and Takeda. The remaining authors have no disclosures. Corresponding author: Lisandro D. Colantonio. 1720 2nd Ave South, RPHB 527C. Birmingham, AL 35294-0013. Phone: 205-259-6415. Fax: 205-975-7058. Email: lcolantonio@uab.edu.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Accepted manuscript
Higher serum urate levels are associated with an increased risk for sudden cardiac death
Lisandro D. Colantonio, Richard J. Reynolds, Tony R. Merriman, Angelo Gaffo, Jasvinder A. Singh, Timothy B. Plante, Ninad S. Chaudhary, Nicole D. Armstrong, Elsayed Z. Soliman, Jeffrey R. Curtis, S. Louis Bridges, Leslie Lang, George Howard, Monika M. Safford, Kenneth G. Saag, Paul Muntner, Marguerite Ryan Irvin
The Journal of Rheumatology Jun 2021, jrheum.210139; DOI: 10.3899/jrheum.210139
Accepted manuscript
Higher serum urate levels are associated with an increased risk for sudden cardiac death
Lisandro D. Colantonio, Richard J. Reynolds, Tony R. Merriman, Angelo Gaffo, Jasvinder A. Singh, Timothy B. Plante, Ninad S. Chaudhary, Nicole D. Armstrong, Elsayed Z. Soliman, Jeffrey R. Curtis, S. Louis Bridges, Leslie Lang, George Howard, Monika M. Safford, Kenneth G. Saag, Paul Muntner, Marguerite Ryan Irvin
The Journal of Rheumatology Jun 2021, jrheum.210139; DOI: 10.3899/jrheum.210139